AQUILA
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
- NCT03301220 ↗
- Completed
- Janssen Research & Development, LLC
- Deep
We haven't built an HCP commentary report on AQUILA (daratumumab SC: daratumumab + rHuPH20 in Smoldering Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 28, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses AQUILA’s comparison of daratumumab with active monitoring in high-risk smoldering myeloma, including how the trial defined high risk amid changing risk-stratification models and the role of imaging at enrollment. Discussion covers whether progression-free survival is an appropriate endpoint, and consideration of safety and quality-of-life assessment. Speakers raise questions about patient selection, when to begin treatment, crossover and subsequent therapy when interpreting overall-survival evidence, and limitations of patient-reported outcome data. Shared decision-making and treatment access are also discussed.
Indexed commentary on AQUILA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 151 | |
| YouTube | 127 | |
| Podcasts | 50 | |
| Bluesky threads | 27 | |
| X videos | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Daratumumab SC: daratumumab + rHuPH20
- Arms
- Arm A: Active Monitoring · No intervention
- Arm B: Daratumumab SC · Experimental
- Enrollment
- 390
- Primary outcomes
- Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Nov 7, 2017
- Primary completion
- May 1, 2024
- Results posted
- Yes
- Registry record
- NCT03301220 · updated Jun 8, 2026
Publications
linked from the registry- Suzuki K, Kosugi H, Ito T, Takamatsu Y, Voorhees PM, Rajkumar SV, Ito M, Sakai C, Takahashi M, Nakatogawa T, Dennis R, Carson R, Dimopoulos MA. Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma. Jpn J Clin Oncol. 2026 Sep 16:hyag146. doi: 10.1093/jjco/hyag146. Online ahead of print. PubMed 42747040
- Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9. PubMed 39652675